Ad5-hGCC-PADRE vaccine (Thomas Jefferson University)

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameAd5-hGCC-PADRE vaccine (Thomas Jefferson University)
Drug Alias NameAd5-GCC-PADREAd5-hGCC-PADRE vaccineAd5-GUCY2C-PADRE
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsColonic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesThomas Jefferson University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSidney Kimmel Cancer Center At Thomas Jefferson University
Active IndicationsN/A
Inactive IndicationsColonic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A